SCHEMBL2773604

SCHEMBL2773604

CCOC(=O)c1nc(-c2cccnc2)c2onc(-c3ccccc3)c2c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CDC7 O00311 3/20 0.45
DBF4 Q9UBU7 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
POLB P06746 1/20 0.44
SLC26A6 Q9BXS9 1/20 0.44
ALDH1A1 P00352 4/20 0.42
ACHE P22303 3/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TARBP2 Q15633 1/20 0.41
MMP2 P08253 1/20 0.41
MMP13 P45452 1/20 0.41
MMP14 P50281 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2774268 0.92 ALDH1A1 (0.47) NPC1RAB9ACDC7DBF4KMT2A
SCHEMBL2776664 0.91 CDC7 (0.50) NPC1RAB9ACDC7DBF4KMT2A
SCHEMBL2775657 0.84 ADORA3 (0.48) NPC1RAB9AKMT2AALDH1A1MAPT
SCHEMBL2776598 0.84 ADORA3 (0.48) NPC1RAB9AKMT2ASLC26A6ALDH1A1
SCHEMBL2775360 0.84 GABRA5 (0.42) NPC1RAB9AKMT2APOLBALDH1A1
SCHEMBL2774171 0.83 TARBP2 (0.46) NPC1RAB9ACDC7DBF4KMT2A
SCHEMBL2777401 0.82 TARBP2 (0.45) NPC1RAB9ACDC7DBF4KMT2A
SCHEMBL2776677 0.81 TARBP2 (0.43) NPC1RAB9AKMT2AALDH1A1MAPT
SCHEMBL3780077 0.80 CDC7 (0.48) NPC1RAB9ACDC7DBF4MEN1
SCHEMBL2776574 0.80 EGLN1 (0.54) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 NPC1 3806/4885RAB9A 4374/4885CDC7 3847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.